

31. Silverman S, Gold DT. Compliance and persistence with osteoporosis medications: a critical review of the literature. *Rev Endocr Metab Disord*. Dec 2010; 11(4): 275–280.
32. Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD. Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. *Osteoporos Int*. Nov 2009; 20(11): 1895–902.
33. Thomson AB, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions. *Can J Gastroenterol*. Nov-Dec 1997; 11(8): 663–667.
34. Vaz-da-Silva M, Loureiro AI, Nunes T, et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. *Clin Drug Investig*. 2005; 25(6): 391–399.
35. Boltin D, Zvidi I, Raskin M, et al. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial. *Dig, Dis*. 2018; 36(4): 257–263.
36. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. *Aliment Pharmacol Ther*. Oct 2000; 14(10): 1267–72.
37. Gardner JD, Sloan S, Miner PB, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther*. Apr 1 2003; 17(7): 945–953.
38. Puchalski TA, Krzyzanski W, Blum RA, Jusko WJ. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. *J Clin Pharmacol*. Mar 2001; 41(3): 251–258.
39. Wilder-Smith C, Rohss K, Bokelund Singh S, Sagar M, Nagy P. The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers. *Aliment Pharmacol Ther*. Nov 2010; 32(10): 1249–1256.
40. Mussig S, Witzel L, Luhmann R, Schneider A. Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH. *Eur J Gastroenterol Hepatol*. Jun 1997; 9(6): 599–602.
41. Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. *Aliment Pharmacol Ther*. Nov 15 2006; 24(10): 1445–1451.
42. Skelin M, Lucijanic T, Amidzic Klaric D, et al. Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. *Clin Ther*. Feb 2017; 39(2): 378–403.
43. Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentration. *J Clin Endocrinol Metab*. Oct 2009; 94(10): 3905–3912.
44. Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. *Arch Intern Med*. Dec 13 2010; 170(22): 1996–2003.
45. Skelin M, Lucijanic T, Liberati-Cizmek AM, et al. Effect of timing of levothyroxine administration on the treatment of hypothyroidism: a three-period crossover randomized study. *Endocrine*. Nov 2018; 62(2): 432–439.
46. Srivastava S, Sharma G, Rathore M, et al. A Crossover Study Evaluating Effect of Timing of Levothyroxine on Thyroid Hormone Status in Patients of Hypothyroidism. *J Assoc Physicians India*. Sep 2018; 66(9): 37–40.
47. Giassi K, Piccoli V, da Costa Rodrigues T, Gorga Bandeira de Mello R. Evaluation of evening versus morning levothyroxine intake in elderly (MONIALE). *Trials*. Dec 17 2019; 20(1): 742.
48. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. *Diabetes Care*. Aug 2013; 36(8): 2154–2161.
49. Ohgaki R, Wei L, Yamada K, et al. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. *J Pharmacol Exp Ther*. Jul 2016; 358(1): 94–102.
50. Málek F. Inhibitory angiotenzin-konvertujícího enzymu v terapii kardiovaskulárních onemocnění – tradiční a nové indikace pro klinické použití lékové skupiny. *Interní med*. 2002; 4(8): 374–378.
51. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. *Pharmacotherapy*. May-Jun 1998; 18(3): 588–99.
52. Špinar J, Vítovec J. Diagnostika a léčba hypertenzní krize. *Interv Akut Kardiolog* 2006; 5: 78–79.
53. Stampfuss J, Kubitz D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. *Int J Clin Pharmacol Ther*. Jul 2013; 51(7): 549–561.
54. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. *Diabetes Obes Metab*. Apr 2017; 19(4): 473–481.
55. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. *N Engl J Med*. Aug 31 1995; 333(9): 541–549.
56. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. *Postgrad Med*. Mar 2010; 122(2): 112–120.
57. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. *Curr Med Res Opin*. Apr 2004; 20(4): 565–572.
58. Venerito M, Wex T, Malfertheiner P. Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Bleeding: Risk Factors and Prevention Strategies. *Pharmaceuticals (Basel)*. Jul 14 2010; 3(7): 2225–2237.
59. Wijma RA, Huttner A, Koch BCP, Mouton JW, Muller AE. Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. *J Antimicrob Chemother* 2018; 73: 2916–2926.
60. Beneš J. Antibiotika – systematika, vlastnosti, použití. Praha: Grada Publishing, 2018.